Skip to main content

Table 1 Clinicopathological implication of Ki67-p53 combination status in surgically resected hormone receptor-positive breast cancers

From: A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer

Variables Cases
  Ki67-p53 combination status
  Total Low Ki67 LIand Negative p53 High Ki67 LI and/or Positive p53 P- value
  (n=150) (n=88) (n=62)  
Age     
   50 71 40 31  
   >50 79 48 31 0.58
Tumor size     
   <5.0 cm 128 78 50  
   5.0 cm 19 8 11 0.12
   Unknown 3 2 1  
Lymph node metastasis
   (−) 84 52 32  
   (+) 63 34 29 0.33
   Unknown 3 2 1  
Stage     
   I or II 129 78 51  
   III 17 7 10 0.13
   Unknown 4 3 1  
Nuclear grade     
   1, 2 115 76 39  
   3 35 12 23 0.0008
HER2 status     
   Negative 142 88 54  
   Positive 8 0 8 0.0006
Basal phenotype marker (CK5/6, CK14, EGFR)
   Negative 140 87 53  
   Positive 10 1 9 0.0016
FOXA1     
   Negative 20 14 6  
   Positive 127 72 55 0.38
   NE 3 2 1  
GATA3     
   Negative 30 18 12  
   Positive 120 70 50 0.99
P-cadherin     
   Low 94 62 32  
   High 56 26 30 0.0019
Chemotherapy     
   No 98 59 39 0.59
   Yes 52 29 23  
  1. Abbreviation: LI labeling index, NE not evaluable.